• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - Product Image

Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  • ID: 2155711
  • June 2012
  • 75 pages
  • GlobalData

FEATURED COMPANIES

  • AB Science
  • Bayer AG
  • Novartis AG
  • MORE

Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market. The report identifies the key trends shaping and driving the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gastrointestinal Stromal Tumors (GIST) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the READ MORE >

FEATURED COMPANIES

  • AB Science
  • Bayer AG
  • Novartis AG
  • MORE

1
1

1.1 List of Tables
1.2 List of Figures
2 Gastrointestinal Stromal Tumors Therapeutics - Introduction
2.1 Overview
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology
2.5 Staging of Gastrointestinal Stromal Tumors
2.6 Diagnosis of Gastrointestinal Stromal Tumors
2.6.1 Computed Tomography Scan
2.6.2 Barium Swallow
2.6.3 Magnetic Resonance Imaging or Positron Emission Tomography
2.6.4 Mutational Analysis
2.7 Treatment of Gastrointestinal Stromal Tumors
2.7.1 Surgery
2.7.2 Radiation Therapy
2.7.3 Chemotherapy
2.7.4 Targeted Therapy
2.8 Treatment and Management Pattern
2.9 Referral Pathway
2.10 GlobalData Pipeline Report Guidance
3 Gastrointestinal Stromal Tumors Therapeutics - Market Characterization
3.1 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – Global
3.2 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Global
3.3 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – The US
3.4 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – The US
3.5 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – The UK
3.6 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – The UK
3.7 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – France
3.8 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – France
3.9 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – Germany
3.10 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Germany
3.11 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – Italy
3.12 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Italy
3.13 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – Spain
3.14 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Spain
3.15 Gastrointestinal Stromal Tumors Market Size (2006–2011) – Japan
3.16 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Japan
3.17 Drivers and Barriers for the Gastrointestinal Stromal Tumors Market
3.17.1 Drivers for the Gastrointestinal Stromal Tumors Market
3.17.2 Barriers for the Gastrointestinal Stromal Tumors Therapeutics Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 Gastrointestinal Stromal Tumors Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Marketed Product Profile
4.3.1 Gleevec (imatinib mesylate)
4.3.2 Sutent (sunitinib malate)
4.4 Key Takeaway
5 Gastrointestinal Stromal Tumors Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Gastrointestinal Stromal Tumors Therapeutics Pipeline Analysis – Pipeline by Clinical Phase of Development
5.3.1 Gastrointestinal Stromal Tumors Therapeutics – Phase III Clinical Pipeline
5.3.2 Gastrointestinal Stromal Tumors Therapeutics – Phase II/III Clinical Pipeline
5.3.3 Gastrointestinal Stromal Tumors Therapeutics – Phase II Clinical Pipeline
5.3.4 Gastrointestinal Stromal Tumors Therapeutics – Phase I/II Clinical Pipeline
5.3.5 Gastrointestinal Stromal Tumors Therapeutics – Phase I Clinical Pipeline
5.3.6 Gastrointestinal Stromal Tumors Therapeutics – Preclinical Phase
5.4 Gastrointestinal Stromal Tumors Therapeutics Pipeline Analysis - Pipeline by Mechanism of Action
5.5 Gastrointestinal Stromal Tumors Technology Trends Analytical Framework
5.6 Molecule Profile for Late-stage Molecules under Clinical Development
5.6.1 Masitinib
5.6.2 Nexavar (sorafenib)
5.6.3 Regorafenib (BAY 73-4506)
5.6.4 Tasigna (nilotinib)
5.7 Key Takeaway
6 Gastrointestinal Stromal Tumors Therapeutics – Clinical Trial Mapping
6.1 Clinical Trial Mapping by Country (The US, EU5 and Japan)
6.2 Clinical Trial Mapping by Phase
6.3 Clinical Trial Mapping by Trial Status
6.4 Clinical Trial Mapping Overall Sponsors
6.5 Clinical Trial Mapping by Prominent Sponsors
6.6 Clinical Trial Mapping by Companies
7 Gastrointestinal Stromal Tumors Therapeutics - Strategic Assessment
7.1 Gastrointestinal Stromal Tumors Therapeutics: Implications for Future Market Competition
8 Gastrointestinal Stromal Tumors Therapeutics - Future Players in the Market
8.1 Introduction
8.2 Company Profiles
8.2.1 Novartis AG
8.2.2 AB Science
8.2.3 Bayer AG
8.3 Gastrointestinal Stromal Tumors Therapeutics Market – Other Future Players
9 Gastrointestinal Stromal Tumors Therapeutics - Licensing and Partnership Deals
10 Gastrointestinal Stromal Tumors Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Bibliography
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Forecasting
10.4.4 Primary Research
10.4.5 Expert Panel Validation
10.5 Contact Us
10.6 Disclaimer

1.1 List of Tables
Table 1: Historical Prevalence of Gastrointestinal Stromal Tumors in Seven Major Markets, 2006–2011 (approximate)
Table 2: Forecast Prevalence of Gastrointestinal Stromal Tumors in Seven Major Markets, 2011–2019 (approximate)
Table 3: Occurrence Rate of Symptoms of Gastrointestinal Stromal Tumors, 2010
Table 4: TNM Staging, Gastrointestinal Stromal Tumors, 2011
Table 5: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Revenue ($m), 2006–2011
Table 6: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Forecast ($m), 2011–2019
Table 7: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Revenue ($m), 2006–2011
Table 8: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Forecast ($m), 2011–2019
Table 9: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Revenue ($m), 2006–2011
Table 10: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Forecast ($m), 2011–2019
Table 11: Gastrointestinal Stromal Tumors Therapeutics Market, France, Revenue ($m), 2006–2011
Table 12: Gastrointestinal Stromal Tumors Therapeutics Market, France, Forecast ($m), 2011–2019
Table 13: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Revenue ($m), 2006–2011
Table 14: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Forecast ($m), 2011–2019
Table 15: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Revenue ($m), 2006–2011
Table 16: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Forecast ($m), 2011–2019
Table 17: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Revenue ($m), 2006–2011
Table 18: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Forecast ($m), 2011–2019
Table 19: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Revenue ($m), 2006–2011
Table 20: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Forecast ($m), 2011–2019
Table 21: Gastrointestinal Stromal Tumors Efficacy Results, Sutent
Table 22: Gastrointestinal Stromal Tumors Therapeutics – Phase III Pipeline
Table 23: Gastrointestinal Stromal Tumors Therapeutics – Phase II/III Pipeline
Table 24: Gastrointestinal Stromal Tumors Therapeutics – Phase II Pipeline
Table 25: Gastrointestinal Stromal Tumors Therapeutics – Phase I/II Pipeline
Table 26: Gastrointestinal Stromal Tumors Therapeutics – Phase I Pipeline
Table 27: Gastrointestinal Stromal Tumors Therapeutics – Preclinical Phase
Table 28: Nexavar Phase II Trial – Summary of Results, 2011
Table 29: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Country, 2012
Table 30: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Phase, 2012
Table 31: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Status, 2012
Table 32: Gastrointestinal Stromal Tumors Therapeutics, Overall Sponsors, 2012
Table 33: Gastrointestinal Stromal Tumors Therapeutics – Prominent Sponsors, 2012
Table 34: Gastrointestinal Stromal Tumors Therapeutics – Companies, 2012
Table 35: Gastrointestinal Stromal Tumors Pipeline, Novartis AG
Table 36: Gastrointestinal Stromal Tumors Pipeline, AB Science
Table 37: Gastrointestinal Stromal Tumors Pipeline, Bayer AG
Table 38: Gastrointestinal Stromal Tumors Therapeutics, Other Future Players
Table 39: Gastrointestinal Stromal Tumors Therapeutics, Global, Deals, 2012

1.2 List of Figures
Figure 1: Distribution of Gastrointestinal Stromal Tumors
Figure 2: Patient Share of Gastrointestinal Stromal Tumors in the Seven Major Markets, 2011
Figure 3: Gastrointestinal Stromal Tumors Therapeutics – Treatment Algorithm
Figure 4: Referral Pathway for Gastrointestinal Stromal Tumors
Figure 5: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Revenue ($m), 2006–2011
Figure 6: Gastrointestinal Stromal Tumors Therapeutics, Global Market Share ($m), 2011
Figure 7: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Forecast ($m), 2011–2019
Figure 8: Gastrointestinal Stromal Tumors Therapeutics, Global Market Share ($m), 2019
Figure 9: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Revenue ($m), 2006–2011
Figure 10: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Forecast ($m), 2011–2019
Figure 11: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Revenue ($m), 2006–2011
Figure 12: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Forecast ($m), 2011–2019
Figure 13: Gastrointestinal Stromal Tumors Therapeutics Market, France, Revenue ($m), 2006–2011
Figure 14: Gastrointestinal Stromal Tumors Therapeutics Market, France, Forecast ($m), 2011–2019
Figure 15: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Revenue ($m), 2006–2011
Figure 16: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Forecast ($m), 2011–2019
Figure 17: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Revenue ($m), 2006–2011
Figure 18: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Forecast ($m), 2011–2019
Figure 19: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Revenue ($m), 2006–2011
Figure 20: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Forecast ($m), 2011–2019
Figure 21: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Revenue ($m), 2006–2011
Figure 22: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Forecast ($m), 2011–2019
Figure 23: Drivers and Barriers for Gastrointestinal Stromal Tumor Therapeutics, 2012
Figure 24: Opportunity and Unmet Need in the Primary (Resectable) Gastrointestinal Stromal Tumors Therapeutics Market, 2012
Figure 25: Opportunity and Unmet Need in the Metastatic/Unresectable Gastrointestinal Stromal Tumors Therapeutics Market, 2012
Figure 26: Gastrointestinal Stromal Tumors Therapeutics Market – Strategic Competitor Assessment, 2012
Figure 27: Gleevec Phase III Trial Results – Progression-free Survival
Figure 28: Gleevec Phase III Trial Results – Overall Response Rate
Figure 29: Sutent – Time to Tumor Progression in Gastrointestinal Stromal Tumor Patients
Figure 30: Gastrointestinal Stromal Tumors Therapeutics – Pipeline by Phase of Development, 2012
Figure 31: Gastrointestinal Stromal Tumors Therapeutics – Clinical Pipeline by Mechanism of Action, 2012
Figure 32: Technology Trends Analytical Framework of the Gastrointestinal Stromal Tumors Pipeline, 2012
Figure 33: Technology Trends Analytical Framework of the Gastrointestinal Stromal Tumors Pipeline, 2012
Figure 34: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Country, 2012
Figure 35: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Phase, 2012
Figure 36: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Status, 2012
Figure 37: Gastrointestinal Stromal Tumors Therapeutics – Overall Sponsors, 2012
Figure 38: Gastrointestinal Stromal Tumors Therapeutics – Prominent Sponsors, 2012
Figure 39: Gastrointestinal Stromal Tumors Therapeutics – Companies, 2012
Figure 40: Implications for Future Market Competition in the Gastrointestinal Stromal Tumors Therapeutics Market, 2012
Figure 41: Gastrointestinal Stromal Tumors Therapeutics – Future Players, 2012
Figure 42: GlobalData Market Forecasting Model

FEATURED COMPANIES

  • AB Science
  • Bayer AG
  • Novartis AG
  • MORE

Resistance to Long-Term Treatment for GIST Increases Need for Research.

Current treatments for gastrointestinal stromal tumors (GIST) are failing to keep the condition under control on a long-term basis, according to a new report by healthcare intelligence experts GlobalData.

The new report* shows that patients undertaking established therapies for gastrointestinal stromal tumors (GISTs) often develop a resistance following long-term use.

This means the race is on to find new treatments, before drug resistance begins to increase patient mortality.

There are only two drugs treatment options presently available for GIST: Gleevec (imatinib mesylate) from Novartis Pharmaceuticals is used as the first line of therapy and adjuvant therapy for primary GIST patients, while Sutent (sunitinib) from Pfizer provides the second line of therapy for metastatic or unresectable GIST patients.

Although these two agents cater well to patients needs, if resistance is developed, no other treatment options are available. GlobalData’s analysis suggests that, as a result, doctors could benefit from more treatment options, as patients often develop resistance to Gleevec and Sutent following a certain amount of drug use.

In terms of pharmaceutical development, this creates an opportunity for new treatments to enter the market, as any new drug able to cater to this untreated, resistant patient pool would reap huge medical and financial rewards.

A strong pipeline is hoped to increase the number of future treatment options for Gleevec and Sutent-resistant patients, with GlobalData analysis showing that the GIST therapeutics pipeline holds 30 molecules in various phases of clinical development. These include 28 first-in-class molecules, and four late-stage molecules, namely Avastin, regorafenib, masitinib, and Tasigna (nilotinib). All have shown good efficacy results in earlier clinical studies for resistant and refractory GIST patients, and are expected to be launched in the forecast period to address the current unmet needs in the GIST market.

GlobalData estimates that the Gastrointestinal Stromal Tumors (GIST) therapeutics market was worth $946.5m in 2011, but will decline to $820m by 2019 due to the patent expiry of Gleevec in 2015.

*Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

This report identifies the key trends shaping and driving the market, and provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of current market leaders. Most importantly, it provides valuable insights on the pipeline products within the global GIST sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData’s team of industry experts.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos